Beigene, Ltd. (NASDAQ:ONC - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $262.41, but opened at $276.59. Beigene shares last traded at $280.00, with a volume of 167,387 shares trading hands.
Analyst Ratings Changes
Several equities research analysts recently commented on ONC shares. Macquarie upped their target price on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. JMP Securities set a $348.00 price target on Beigene in a research note on Friday, February 28th. Sanford C. Bernstein set a $259.00 price target on Beigene in a research note on Thursday, March 13th. Bank of America raised Beigene from a "neutral" rating to a "buy" rating and upped their price target for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Wall Street Zen raised Beigene from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $319.00.
Read Our Latest Report on ONC
Beigene Stock Up 5.4%
The company has a market capitalization of $32.74 billion, a PE ratio of -33.56, a PEG ratio of 7.73 and a beta of 0.30. The firm has a 50 day moving average of $240.18. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.
Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. On average, equities analysts forecast that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.
Insider Transactions at Beigene
In related news, insider Xiaodong Wang sold 41,760 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $261.28, for a total transaction of $10,911,052.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Titus B. Ball sold 134 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $258.36, for a total value of $34,620.24. The disclosure for this sale can be found here. Insiders sold a total of 228,258 shares of company stock valued at $58,317,119 over the last ninety days. 6.62% of the stock is currently owned by insiders.
Beigene Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Further Reading
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
